Sutro Biopharma Inc. (NASDAQ: STRO) reported Q2 EPS of ($2.33), $0.13 worse than the analyst estimate of ($2.20). Revenue for the quarter came in at $9.84 million versus the consensus estimate of $11.58 million.

For earnings history and earnings-related data on Sutro Biopharma Inc. (STRO) click here.